Navigation Links
TG02 Potently Inhibits the Proliferation and Survival of Multiple Myeloma Cell Lines through Depletion of the Key Survival Protein MCL-1
Date:4/5/2013

San Diego (PRWEB) April 05, 2013

Tragara Pharmaceuticals, Inc. today announced that profiling biological data on TG02, the Company's unique oral kinase inhibitor, has been published in Clinical Cancer Research. Researchers from the Instituto de Biologia Molecular y Celular del Cancer, University of Salamanca, utilized in vivo models and patient-derived ex vivo samples to evaluate the antitumor activity and mechanism of action of TG02 in multiple myeloma. The data show that TG02 potently and consistently inhibited proliferation and survival of multiple myeloma cell lines, even under protective bone marrow niche conditions, and selectively induced apoptosis of primary patient-derived malignant plasma cells. The study also reported that that TG02 induced robust activation of the intrinsic pathways of apoptosis via its ability to deplete the key survival protein Mcl-1.

In this study, TG02 displayed significant single agent activity in two multiple myeloma xenograft models. Additionally, TG02 enhanced the in vivo activity of bortezomib and lenalidomide, two currently approved treatments for myeloma. As most of the treatment regimens for myeloma patients are based upon drug combinations, TG02’s demonstrated ability to augment the antitumor activity of other agents is a clinically important observation. The researchers also reported that the studied TG02 combinations were well tolerated by the animals.

TG02 is currently in phase I clinical testing in patients with multiple myeloma in the United States. An additional phase I clinical study in patients with chronic lymphocytic leukemia is also underway and a phase I study in acute leukemia has been completed.

1. Álvarez-Fernández, Stela, et al. "Potent antimyeloma activity of a novel ERK5/CDK inhibitor." Clinical Cancer Research (2013).

About TG02
TG02 is a unique, oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin dependent kinases equipotently with JAK2, FLT3, and ERK5 inhibition. TG02 exerts its antitumor activity via its potent CDK9 inhibition, which leads to the depletion of key survival proteins, such as Mcl-1, resulting in p53-independent apoptosis of a wide range of tumor cells. TG02 development will initially focus on the treatment of hematologic malignancies, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), because of the consistent antitumor activity that was observed across a broad spectrum of hematologic cancer models, including those resistant to currently available therapies. In these models, TG02 demonstrated both single agent activity and synergy when administered with current standard of care therapies. Subsequent development will focus on an important group of solid tumors with unmet medical need, such as small cell lung cancer, triple negative breast cancer, and melanoma, which will also benefit from this mechanism of action, complemented with the benefits of inhibiting both JAK2 and ERK5. These pathways affect disease progression and survival in hematologic malignancies and solid tumors.

TG02 is currently being evaluated in two separate phase I clinical trials in patients with MM and CLL in the United States. Subsequent phase Ib clinical studies of TG02 in combination with other agents are planned for later in 2013.

In early 2010, TG02 was selected by the Multiple Myeloma Research Foundation as a winner of its Biotech Investment Award, which represents a multi-year research grant commitment to fund the early-stage drug development of novel compounds that show potential in treating MM.

About Tragara
Tragara Pharmaceuticals, Inc. is a privately held pharmaceutical company based in San Diego, Calif. The company is focused on the clinical and commercial development of proprietary medicines for the treatment of cancer. TG02 is a unique, oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin dependent kinases equipotently with JAK2, FLT3, and ERK5 inhibition. TG02 exerts its antitumor activity via its potent CDK9 inhibition, which leads to the depletion of key survival proteins, such as Mcl-1, resulting in p53-independent apoptosis of a wide range of tumor cells. Tragara is managed by a team of entrepreneurs with both Big Pharma and Biotech experience in the development and commercialization of oncology therapeutics. Its investors include: Domain Associates, Mitsubishi International Corporation, Morganthaler Ventures, and ProQuest Investments.

Tragara strives to provide much-needed therapies that will contribute to patient health through better survival and an increase in the quality of life. For more information, visit http://www.tragarapharma.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10603791.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Bloodstream scavenger inhibits clotting without increased bleeding
2. Molecule found that inhibits recovery from stroke
3. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
4. Kentucky team inhibits Alzheimers biomarkers in animal model by targeting astrocytes
5. CWRU School of Medicine researchers discover gene that permanently stops cancer cell proliferation
6. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
7. Cancer Care Costs Higher in U.S. Than Europe, But Survival Longer
8. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
9. Hispanics Seem to Have Better Odds of Lung Cancer Survival
10. Equal access to care helps close survival gap for young African-American cancer patients
11. Heart Attack Survival Varies Widely Among Hospitals, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 22, 2017 , ... The National Academy of Certified Care ... April 2017 testing period. NACCM, a nonprofit organization, has provided the premier certification ... is periodically re-calibrated to ensure that newly certified professionals are prepared to work ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes ... emergency room, fewer hospital admissions, and better blood pressure and glycemic control, a ... The study can be found here . , The study comes as ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... Doctors ... recent addition of esteemed ophthalmologist, Dr. Steven H. Rauchman, practicing at North Valley ... in auto accidents, product liability, premise liability and other personal injury cases. These ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Global Endoscopy Market is poised to grow ... reach approximately $47.6 billion by 2025. This industry ... segments on global as well as regional levels presented in the ...
(Date:2/23/2017)... Ga., Feb. 23, 2017  MiMedx Group, Inc. (NASDAQ: ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, ... and full year ended December 31, 2016. ... Revenue is a 31% increase over full year 2015 ...
(Date:2/23/2017)... Feb. 23, 2017   SeraCare Life Sciences ... in vitro diagnostics manufacturers and clinical laboratories, is ... Implementation of NGS-Based Tests" to be hosted by ... at 11am Eastern Standard Time (US). ... the need for improved performance and global standardization ...
Breaking Medicine Technology: